Mabsoft Therapeutics

Mabsoft Therapeutics is a Shanghai-based biopharmaceutical company founded in 2020 that specializes in the discovery and development of next-generation Immuno-Stimulating Antibody Conjugates (ISACs) and novel antibodies for oncology. The company's core innovation strategy focuses on overcoming tumor resistance by integrating immune agonists, such as TLR7/8 modulators, into antibody constructs to enhance anti-tumor immunity. Mabsoft has established a significant strategic partnership with WuXi XDC to leverage their end-to-end CRDMO platform for drug discovery, process development, and GMP manufacturing. With a clinical development goal of achieving high durable response rates in solid tumors, the company is advancing a pipeline of globally innovative therapeutics. The company is backed by prominent investors such as 6 Dimensions Capital and utilizes proprietary platforms for both ISACs and agonistic multivalent bispecific antibodies.